Updated Jul 16, 2026 · Last SEC filing 2026-07-13
BridgeBio Pharma, Inc. (BBIO) has filed 24 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 6 Form 8-K material event filings were reported by BBIO in the last 90 days. 10 Form 144 notices of proposed sale were filed for BBIO stock. InsiderAlpha tracks every BBIO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001743881 |
| Form 4 filings (90d) | 24 |
|---|---|
| Form 8-K filings (90d) | 6 |
| Form 144 notices (90d) | 10 |
| Latest Form 4 filing | 2026-07-13 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Cook Jennifer E. | Director | M — Option exercise [10b5-1] | 19.0K | $8.45 | $161K | SEC | |
| Ellis Andrea | Director | M — Option exercise [10b5-1] | 17.2K | $16.75 | $288K | SEC | |
| Cook Jennifer E. | Director | M — Option exercise [10b5-1] | 17.2K | $16.75 | $288K | SEC | |
| Cook Jennifer E. | Director | M — Option exercise [10b5-1] | 112.4K | $29.00 | $3.26M | SEC | |
| Cook Jennifer E. | Director | S — Open-market sale [10b5-1] | 36.2K | $84.00 | $3.04M | SEC | |
| Cook Jennifer E. | Director | S — Open-market sale [10b5-1] | 112.4K | $90.00 | $10.12M | SEC | |
| Ellis Andrea | Director | S — Open-market sale [10b5-1] | 17.2K | $84.00 | $1.44M | SEC | |
| Cook Jennifer E. | Director | M — Option exercise | 20.0K | $8.45 | $169K | SEC | |
| Cook Jennifer E. | Director | S — Open-market sale | 37.2K | $70.00 | $2.60M | SEC | |
| Cook Jennifer E. | Director | M — Option exercise | 17.2K | $16.75 | $288K | SEC | |
| Cook Jennifer E. | Director | S — Open-market sale | 2.2K | $68.57 | $151K | SEC | |
| Valantine Hannah | Director | S — Open-market sale | 2.2K | $68.57 | $151K | SEC | |
| Cook Jennifer E. | Director | A — Grant or award | 4.0K | $0.00 | — | SEC | |
| DANIELS RONALD J | Director | A — Grant or award | 4.0K | $0.00 | — | SEC | |
| Valantine Hannah | Director | S — Open-market sale | 2.8K | $68.00 | $191K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for BridgeBio Pharma, Inc. (BBIO). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Kumar Neil | 40 | $15.01M |
| Cook Jennifer E. | 22 | $26.93M |
| Valantine Hannah | 6 | $459K |
| Scott Randal W. | 6 | $839K |
| Ellis Andrea | 5 | $1.73M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in BBIO insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live BBIO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.